Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 30
Filter
1.
Nat Commun ; 12(1): 6364, 2021 11 04.
Article in English | MEDLINE | ID: mdl-34737305

ABSTRACT

Lysocin E is a lipopeptide with antibiotic activity against methicillin-resistant Staphylococcus aureus. For unclear reasons, the antibacterial activity of lysocin E in a mouse systemic infection model is higher than expected from in vitro results, and the in vitro activity is enhanced by addition of bovine serum. Here, we confirm that serum from various species, including humans, increases lysocin E antimicrobial activity, and identify apolipoprotein A-I (ApoA-I) as an enhancing factor. ApoA-I increases the antibacterial activity of lysocin E when added in vitro, and the antibiotic displays reduced activity in ApoA-I gene knockout mice. Binding of ApoA-I to lysocin E is enhanced by lipid II, a cell-wall synthesis precursor found in the bacterial membrane. Thus, the antimicrobial activity of lysocin E is potentiated through interactions with host serum proteins and microbial components.


Subject(s)
Anti-Bacterial Agents/pharmacology , Apolipoprotein A-I/blood , Methicillin-Resistant Staphylococcus aureus/drug effects , Peptides, Cyclic/pharmacology , Staphylococcal Infections/drug therapy , Animals , Disease Models, Animal , Female , Lipopeptides/pharmacology , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Mice , Mice, Inbred C57BL , Mice, Inbred ICR , Microbial Sensitivity Tests , Staphylococcal Infections/blood , Staphylococcal Infections/microbiology
2.
Drug Discov Ther ; 14(4): 177-180, 2020 Sep 08.
Article in English | MEDLINE | ID: mdl-32830169

ABSTRACT

This study was performed with the aim of making a very simple recipe of silkworm diet for research purposes, especially screening of drug candidates. We prepared a diet containing mulberry leaves powder and soybean flour at different ratios, fed them to fifth instar silkworm larvae, and observed their growth. We selected the diet with 1:1 ratio of mulberry powder and soybean flour, named MS-11, and used for further experiments. MS-11 diet was available for oral administration of drugs in silkworm hyperglycemic model and infection model. The availability of a simple artificial diet for experiments that require feeding silkworms will enhance the use of silkworms for biological, biotechnological, and pharmacological researches.


Subject(s)
Bombyx/growth & development , Glycine max/chemistry , Morus/chemistry , Plant Extracts/administration & dosage , Animal Feed , Animals , Drug Evaluation, Preclinical , Larva/growth & development , Models, Animal
3.
Drug Discov Ther ; 13(3): 133-136, 2019.
Article in English | MEDLINE | ID: mdl-31327788

ABSTRACT

Using a silkworm evaluation system, we previously evaluated various substances that suppress postprandial hyperglycemia. Enterococcus faecalis YM0831, a lactic acid bacterium that inhibits glucose uptake by the human intestinal Caco-2 cell line, exhibited hyperglycemia-suppressing effects in the silkworm system. In the present study, we found that Kothala himbutu (Salacia reticulata) extract, a traditional medicine containing α-glucosidase inhibitors, suppressed sucrose-induced hyperglycemia in the silkworm system. Moreover, combined oral administration of lactic acid bacteria YM0831 with Kothala himbutu extract had stronger suppressive effects on sucrose-induced hyperglycemia than single administration of either component. These findings suggest that the silkworm system provides a simple way to evaluate the effects of supplements on the suppression of blood glucose level induced by sucrose ingestion.


Subject(s)
Enterococcus faecalis/physiology , Hyperglycemia/therapy , Plant Extracts/administration & dosage , Salacia/chemistry , Animals , Blood Glucose/metabolism , Bombyx , Combined Modality Therapy , Disease Models, Animal , Hyperglycemia/chemically induced , Hyperglycemia/metabolism , Plant Extracts/therapeutic use , Sucrose/adverse effects , Treatment Outcome
4.
Yakugaku Zasshi ; 138(7): 895-899, 2018.
Article in Japanese | MEDLINE | ID: mdl-29962465

ABSTRACT

 The emergence of antimicrobial resistant (AMR) bacteria has become a serious threat to public health. It is important that we find a mechanistically novel antibiotic to combat AMR. However, finding compounds which are both therapeutically effective and safe is difficult in the development of antibiotics. To solve these problems, we have focused on the silkworm model, which is economical and poses fewer ethical issues, as a means to evaluate the therapeutic effectiveness of test compounds in early stages of antibiotic development. Actually, the silkworm has pharmacokinetic parameters similar to mammals, and we revealed that antibiotics showed ED50s consistent with mammalian models. Thus, we screened therapeutically effective samples from natural products using the silkworm model, and found 23 candidates out of 15000 samples. We ultimately identified a novel antibiotic, lysocin E, and found that it demonstrates a potent therapeutic effect in the mouse systemic infection model. Furthermore, since the target of lysocin E is menaquinone on the bacterial membrane, it belongs to a novel class of antibiotics. In addition, we found a novel antibacterial agent named nosokomycin, GPI0363, and an antifungal agent, VL-2397 (ASP2397), using the silkworm model. In this report, we introduce the usefulness of the silkworm model in the development of antibiotics.


Subject(s)
Anti-Bacterial Agents , Bombyx , Disease Models, Animal , Drug Discovery/methods , Animals , Anti-Bacterial Agents/pharmacology , Antifungal Agents/pharmacology , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Mice , Peptides, Cyclic/pharmacology
5.
Sci Rep ; 8(1): 1578, 2018 01 25.
Article in English | MEDLINE | ID: mdl-29371643

ABSTRACT

Poor pharmacokinetic parameters are a major reason for the lack of therapeutic activity of some drug candidates. Determining the pharmacokinetic parameters of drug candidates at an early stage of development requires an inexpensive animal model with few associated ethical issues. In this study, we used the silkworm infection model to perform structure-activity relationship studies of an antimicrobial agent, GPI0039, a novel nitrofuran dichloro-benzyl ester, and successfully identified compound 5, a nitrothiophene dichloro-benzyl ester, as a potent antimicrobial agent with superior therapeutic activity in the silkworm infection model. Further, we compared the pharmacokinetic parameters of compound 5 with a nitrothiophene benzyl ester lacking chlorine, compound 7, that exerted similar antimicrobial activity but had less therapeutic activity in silkworms, and examined the metabolism of these antimicrobial agents in human liver fractions in vitro. Compound 5 had appropriate pharmacokinetic parameters, such as an adequate half-life, slow clearance, large area under the curve, low volume of distribution, and long mean residence time, compared with compound 7, and was slowly metabolized by human liver fractions. These findings suggest that the therapeutic effectiveness of an antimicrobial agent in the silkworms reflects appropriate pharmacokinetic properties.


Subject(s)
Anti-Infective Agents/pharmacology , Anti-Infective Agents/pharmacokinetics , Bacteria/drug effects , Bombyx , Animals , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/chemistry , Chromatography, High Pressure Liquid , Humans , Inactivation, Metabolic , Microbial Sensitivity Tests , Structure-Activity Relationship
6.
Med Mycol J ; 58(4): E131-E137, 2017.
Article in Japanese | MEDLINE | ID: mdl-29187715

ABSTRACT

The development of effective drugs against fungal diseases involves performing infection experiments in animals to evaluate candidate therapeutic compounds. Cryptococcus neoformans is a pathogenic fungus that causes deep mycosis, resulting in respiratory illness and meningitis. Here we describe a silkworm system established to evaluate the safety and efficacy of therapeutic drugs against infection by Cryptococcus neoformans and the advantages of this system over other animal models. The silkworm assay system has two major advantages: 1) silkworms are less expensive to rear and their use is less problematic than that of mammals in terms of animal welfare, and 2) in vivo screenings for identifying candidate drugs can be easily performed using a large number of silkworms. The pharmacokinetics of compounds are consistent between silkworms and mammals. Moreover, the ED50 values of antibiotics are concordant between mammalian and silkworm infection models. Furthermore, the body size of silkworms makes them easy to handle in experimental procedures compared with other invertebrate infectious experimental systems, and accurate amounts of pathogens and chemicals can be injected fairly easily. These advantages of silkworms as a host animal make them useful for screening candidate drugs for cryptococcosis.


Subject(s)
Antifungal Agents/therapeutic use , Bombyx , Cryptococcosis/drug therapy , Disease Models, Animal , Drug Evaluation, Preclinical/methods , Animals , Antifungal Agents/administration & dosage , Antifungal Agents/pharmacokinetics , Cryptococcosis/microbiology , Cryptococcus neoformans/pathogenicity , Dose-Response Relationship, Drug
7.
Drug Discov Ther ; 11(5): 230-237, 2017 Nov 22.
Article in English | MEDLINE | ID: mdl-29021502

ABSTRACT

Vegetables are eaten as part of a healthy diet throughout the world, and some are also applied topically as a traditional medicine. We evaluated the innate immunostimulating activities of hot water extracts of various vegetables using the silkworm muscle contraction assay system, and found that broccoli, Brassica oleracea var. italica, contains a strong innate immunostimulant. We purified the innate immunostimulant from broccoli, and characterized the chemical structure by chemical analyses and NMR spectroscopy. The innate immunostimulant comprised galacturonic acid, galactose, glucose, arabinose, and rhamnose, and had a pectic-like polysaccharide structure. To determine the structural motif involved in the innate immunostimulating activity, we modified the structure by chemical and enzymatic treatment, and found that the activity was attenuated by pectinase digestion. These findings suggest that a pectic-like polysaccharide purified from broccoli has innate immune-stimulating activity, for which the polygalacturonic acid structure is necessary.


Subject(s)
Adjuvants, Immunologic/pharmacology , Brassica , Immunity, Innate/drug effects , Larva/drug effects , Muscle Contraction/drug effects , Pectins/pharmacology , Plant Extracts/pharmacology , Adjuvants, Immunologic/chemistry , Animals , Arabinose/chemistry , Bombyx , Galactose/chemistry , Glucose/chemistry , Hexuronic Acids/chemistry , Immunity, Innate/immunology , Larva/chemistry , Larva/immunology , Magnetic Resonance Spectroscopy , Molecular Structure , Muscle Contraction/immunology , Pectins/chemistry , Plant Extracts/chemistry , Polysaccharides/chemistry , Polysaccharides/pharmacology , Rhamnose/chemistry
8.
Drug Discov Ther ; 11(5): 238-245, 2017 Nov 22.
Article in English | MEDLINE | ID: mdl-29021503

ABSTRACT

We screened innate immunostimulant-producing bacteria using a silkworm muscle contraction assay, and isolated Rhizobium sp. strain M2 from soil. We purified the innate immunostimulant from strain M2, and characterized the chemical structure by nuclear magnetic resonance spectroscopy and chemical analyses. The innate immunostimulant (M2 EPS) comprised glucose, galactose, pyruvic acid, and succinic acid with a molar ratio of 6.8:1.0:0.9:0.4, and had a succinoglycan-like high molecular-weight heteropolysaccharide structure. To determine the structural motif involved in the innate immunostimulating activity, we modified the M2 EPS structure chemically, and found that the activity was increased by removal of the succinic and pyruvic acid substitutions. Strong acid hydrolysis completely inactivated the M2 EPS. Unmasking of the ß-1,3/6-glucan structure of the side-chain by deacylation and depyruvylation may enhance the innate immune-stimulating activity of M2 EPS. These findings suggest that the succinoglycan-like polysaccharide purified from strain M2 has innate immune-stimulating activity, and its glycan structure is necessary for the activity.


Subject(s)
Adjuvants, Immunologic/pharmacology , Immunity, Innate/drug effects , Larva/drug effects , Muscle Contraction/drug effects , Polysaccharides, Bacterial/pharmacology , Rhizobium , Adjuvants, Immunologic/chemistry , Animals , Bombyx , Galactose/chemistry , Glucose/chemistry , Immunity, Innate/immunology , Larva/immunology , Magnetic Resonance Spectroscopy , Molecular Structure , Muscle Contraction/immunology , Polysaccharides, Bacterial/chemistry , Pyruvic Acid/chemistry , Succinic Acid/chemistry
9.
Sci Rep ; 7(1): 12289, 2017 09 25.
Article in English | MEDLINE | ID: mdl-28947778

ABSTRACT

Animal models of pathogenic infection are needed to evaluate candidate compounds for the development of anti-infectious drugs. Dermatophytes are pathogenic fungi that cause several infectious diseases. We established a silkworm dermatophyte infection model to evaluate anti-fungal drugs. Injection of conidia of the dermatophyte Arthroderma vanbreuseghemii into silkworms was lethal. A. vanbreuseghemii conidia germinated in liquid culture were more potent against silkworms than non-germinated conidia. Germinated conidia of other dermatophytes, Arthroderma benhamiae, Trichophyton rubrum, and Microsporum canis, also killed silkworms. Injection of heat-treated germinated A. vanbreuseghemii conidia did not kill silkworms, suggesting that only viable fungi are virulent. Injecting terbinafine or itraconazole, oral drugs used clinically to treat dermatophytosis, into the silkworm midgut had therapeutic effects against infection with germinated A. vanbreuseghemii conidia. When silkworms were injected with A. vanbreuseghemii expressing enhanced green fluorescent protein (eGFP), mycelial growth of the fungus was observed in the fat body and midgut. Injection of terbinafine into the silkworm midgut, which corresponds to oral administration in humans, inhibited the growth of A. vanbreuseghemii expressing eGFP in the fat body. These findings suggest that the silkworm infection model with eGFP-expressing dermatophytes is useful for evaluating the therapeutic activity of orally administered anti-fungal agents against dermatophytes.


Subject(s)
Antifungal Agents/therapeutic use , Arthrodermataceae/drug effects , Bombyx/microbiology , Drug Evaluation, Preclinical/methods , Tinea/drug therapy , Animals , Arthrodermataceae/genetics , Arthrodermataceae/pathogenicity , Disease Models, Animal , Genes, Reporter/genetics , Green Fluorescent Proteins/genetics , Humans , Spores, Fungal/pathogenicity , Tinea/microbiology , Treatment Outcome
10.
Drug Discov Ther ; 11(2): 64-69, 2017 May 30.
Article in English | MEDLINE | ID: mdl-28458297

ABSTRACT

Clove oil is used in fish anesthesia and expected to have a mechanism via glutamic receptor. The present study explores the activities of clove oil and its major compound, eugenol, in comparison with L-glutamic acid on glutamic receptor of silkworm muscle and fish anesthesia. It was found that clove oil and eugenol had similar effects to L-glutamic acid on inhibition of silkworm muscle contraction after treated with D-glutamic acid and kainic acid. Anesthetic activity of the test samples was investigated in goldfish. The results demonstrated that L-glutamic acid at 20 and 40 mM could induce the fish to stage 3 of anesthesia that the fish exhibited total loss of equilibrium and muscle tone, whereas clove oil and eugenol at 60 ppm could induce the fish to stage 4 of anesthesia that the reflex activity of the fish was lost. These results suggest that clove oil and eugenol have similar functional activities and mechanism to L-glutamic acid on muscle contraction and fish anesthesia.


Subject(s)
Anti-Infective Agents/pharmacology , Clove Oil/pharmacology , Eugenol/pharmacology , Muscle Contraction/drug effects , Muscle Tonus/drug effects , Anesthesia , Animals , Bombyx , Glutamic Acid/pharmacology , Goldfish , Kainic Acid/pharmacology , Postural Balance/drug effects , Receptors, Glutamate , Reflex/drug effects
11.
Drug Discov Ther ; 11(2): 70-77, 2017 May 30.
Article in English | MEDLINE | ID: mdl-28458298

ABSTRACT

In the present study, the fractionated extracts of Sesbania grandiflora bark were prepared and evaluated for their biological activities. The ethyl acetate fractionate (EAF) showed high antioxidant activity along with free radical scavenging and reducing mechanisms. The free radical scavenging antioxidant activity of EAF was 69.3 ± 3.6% where its Trolox equivalent antioxidant capacity was 13.6 ± 0.7 mM/mg. EAF exhibited the reducing power equivalent to ferrous sulfate at 152 ± 2 mM/mg and equivalent to gallic acid at 1.05 ± 0.01 mM/mg. In addition, EAF presented high potential on inhibition of bacterial growth with the minimum bactericidal concentration less than 1 mg/mL. Further isolation of EAF using normal-phase open column of silica gel 60, showed that the fractions eluted with the mixture of chloroform and methanol at the ratios of 4:1, 3:2, and 2:3 possessed antibacterial activity. The recovery activity of total different active fractions was 5% EAF, 20 times less than that of EAF. The chromatogram of EAF from a high-performance liquid chromatography was compared with caffeic acid, catechin, coumaric acid, ellagic acid, gallic acid, quercetin, syringin, naringic acid, trans-cinnamic acid, and vanilic acid. The result demonstrated that one major compound of EAF was gallic acid. These results suggest that the fractionated extracts of S. grandiflora bark contained antioxidant and antibacterial activities.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antioxidants/pharmacology , Plant Bark , Plant Extracts/pharmacology , Sesbania , Staphylococcus aureus/drug effects , Caffeic Acids/chemistry , Catechin/chemistry , Chromatography, Liquid , Cinnamates/chemistry , Coumaric Acids/chemistry , Ellagic Acid/chemistry , Free Radical Scavengers/pharmacology , Gallic Acid/chemistry , Glucosides/chemistry , Microbial Sensitivity Tests , Phenylpropionates/chemistry , Plant Extracts/chemistry , Quercetin/chemistry , Staphylococcus aureus/growth & development , Vanillic Acid/chemistry
12.
Yakugaku Zasshi ; 137(4): 389-392, 2017.
Article in Japanese | MEDLINE | ID: mdl-28381711

ABSTRACT

In this symposium, we reported the identification and mechanistic analysis of a novel antibiotic named lysocin E. Lysocin E was identified by screening for therapeutic effectiveness in a silkworm Staphylococcus aureus infection model. The advantages of the silkworm infection model for screening and purification of antibiotics from the culture supernatant of soil bacteria are: 1) low cost; 2) no ethical issues; 3) convenient for evaluation of the therapeutic effectiveness of antibiotics; and 4) pharmacokinetics similar to those of mammals. Lysocin E has remarkable features compared with known antibiotics such as a novel mechanism of action and target. Here, we summarize our reports presented in this symposium.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bombyx , Disease Models, Animal , Drug Evaluation, Preclinical/economics , Drug Evaluation, Preclinical/ethics , Peptides, Cyclic/therapeutic use , Staphylococcal Infections/drug therapy , Animals , Anti-Bacterial Agents/pharmacokinetics , Peptides, Cyclic/pharmacokinetics
13.
Pharm Biol ; 55(1): 1256-1262, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28253823

ABSTRACT

CONTEXT: Antibiotic resistance is a serious problem worldwide. Searching for new potential agents is, therefore, essential. The bark of Sesbania grandiflora (L.) Pers. (Fabaceae) has been used in folk medicine against various diseases. OBJECTIVE: To investigate the antibacterial activity of S. grandiflora bark and explore the therapeutic effect of the highest potent fraction. MATERIALS AND METHODS: Bacteria and healthy silkworms were exposed to three fractionated extracts (3.1-400 mg/mL) of S. grandiflora bark from hexane (HXF), chloroform (CFF), and ethyl acetate (EAF). The sets of bacteria were incubated at 37 °C while silkworms were kept at 27 °C for 24 h. To evaluate the therapeutic effect, silkworms infected with bacteria were exposed to the extracts (0.5-60 mg/mL) and incubated at 27 °C for 52 h. Qualitative analysis of the most potent extract was done using HPLC. RESULTS: EAF showed the highest activity with MIC against methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci (VRE) of 1.6 and 0.4 mg/mL, respectively, and against Gram-negative Escherichia coli and Pseudomonas aeruginosa of 6.2 and 3.1 mg/mL, respectively. It is nontoxic to silkworms with LC50 >400 mg/mL and has high therapeutic effect on infected silkworms with EC50 of 1.9 mg/mL. EAF consists of at least five major compounds, one of them is gallic acid. The activity of EAF is higher than the sum of individual activities of separated compounds. DISCUSSION AND CONCLUSION: These results suggest that EAF is a promising antibacterial extract, suitable for further investigation in rodents infected with drug resistant bacteria.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bombyx/drug effects , Bombyx/microbiology , Plant Extracts/pharmacology , Sesbania , Animals , Anti-Bacterial Agents/isolation & purification , Dose-Response Relationship, Drug , Escherichia coli/drug effects , Escherichia coli/physiology , Methicillin-Resistant Staphylococcus aureus/drug effects , Methicillin-Resistant Staphylococcus aureus/physiology , Microbial Sensitivity Tests/methods , Plant Bark , Plant Extracts/isolation & purification , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/physiology
14.
Drug Discov Ther ; 11(1): 1-5, 2017 Mar 22.
Article in English | MEDLINE | ID: mdl-28228617

ABSTRACT

The silkworm infection model has the potential to replace conventional animal models for evaluation of the efficacy and toxicity of investigational antifungal agents. Silkworms are relatively inexpensive, can be simply grown in large numbers and can be easily infected with pathogenic fungi, including mutant strains. Antifungal agents can then be injected into the silkworm either via the hemolymph to mimic intravenous administration or directly into the gut for oral administration, and their antifungal effect can be evaluated. Common features regarding the mechanisms of pharmacokinetics between the silkworm and mammals result in consistent therapeutic effectiveness of antifungal agents. ASP2397, a promising new antifungal agent, was discovered using the silkworm model. The conclusion is that silkworms can be a more ethical and less expensive alternative to standard animal models, particularly for the identification and testing of new antifungal agents.


Subject(s)
Antifungal Agents/pharmacology , Bombyx/microbiology , Coordination Complexes/pharmacology , Disease Models, Animal , Peptides, Cyclic/pharmacology , Animals , Drug Evaluation, Preclinical , Virulence
15.
Drug Discov Ther ; 10(1): 1-2, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26971551

ABSTRACT

For this special issue, we, the Editors of Drug Discoveries & Therapeutics, have asked researchers who are using silkworms to actively develop drugs and study foods to summarize their recent work. Our profound hope is that this special issue encourages researchers who are helping to develop the new field of "using silkworms as a laboratory animal to evaluate medicines and foods".


Subject(s)
Bombyx/drug effects , Dietary Supplements , Drug Discovery/methods , High-Throughput Screening Assays , Animals , Bombyx/embryology , Bombyx/immunology , Bombyx/metabolism , Humans , Larva/drug effects , Models, Animal
16.
Drug Discov Ther ; 10(1): 14-8, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26902904

ABSTRACT

Silkworm shows hyperglycemia after intake of diet containing large amount of glucose. The hyperglycemic silkworm model is useful for evaluation of anti-diabetic drugs. A hot water extract of Rehmanniae Radix, an herbal medicine, showed hypoglycemic effect against the hyperglycemic silkworms. This method is applicable for quick and simple evaluation of the hypoglycemic activities of different batches of Rehmanniae Radix. Our findings suggest that silkworms have a lot of merit as experimental animals for evaluation of various herbal medicines.


Subject(s)
Bombyx/drug effects , Diabetes Mellitus/drug therapy , Drug Discovery/methods , Glucose/metabolism , Hypoglycemic Agents/pharmacology , Plant Extracts/pharmacology , Rehmannia/chemistry , Animals , Bombyx/embryology , Bombyx/metabolism , Diabetes Mellitus/metabolism , Disease Models, Animal , Humans , Hypoglycemic Agents/isolation & purification , Larva/drug effects , Larva/metabolism , Phytotherapy , Plant Extracts/isolation & purification , Plants, Medicinal , Species Specificity
17.
Sci Rep ; 5: 11180, 2015 Jun 10.
Article in English | MEDLINE | ID: mdl-26061948

ABSTRACT

In drug development, the toxicity of candidate chemicals must be carefully examined in an animal model. Here we developed a live imaging technique using silkworms for a noninvasive toxicity test applicable for drug screening. Injection of carbon tetrachloride, a tissue-injuring chemical, into transgenic silkworms expressing green fluorescent protein (GFP) induced leakage of GFP from the tissues into the hemolymph. The leakage of GFP was suppressed by pre-administration of either cimetidine, a cytochrome P450 inhibitor, or N-acetyl cysteine, a free-radical scavenger. The transgenic silkworm was made transparent by feeding a diet containing chemicals that inhibit uric acid deposition in the epithelial cells. In the transparent silkworms, GFP fluorescence in the fat body could be observed from outside the body. Injection of salicylic acid or iron sulfate, tissue-injuring chemicals, into the transparent silkworms decreased the fluorescence intensity of the GFP in the fat body. These findings suggest that the transparent GFP-expressing silkworm model is useful for evaluating the toxicity of chemicals that induce tissue injury.


Subject(s)
Bombyx/drug effects , Bombyx/genetics , Gene Expression , Green Fluorescent Proteins/genetics , Toxicity Tests , Animals , Animals, Genetically Modified , Bombyx/metabolism , Catalysis , Cytochrome P-450 Enzyme System/metabolism , Drug Evaluation, Preclinical/methods , Green Fluorescent Proteins/metabolism , Hemolymph/metabolism , Phenotype , Toxicity Tests/methods
18.
Sci Rep ; 5: 10722, 2015 May 29.
Article in English | MEDLINE | ID: mdl-26024298

ABSTRACT

We previously reported that sugar levels in the silkworm hemolymph, i.e., blood, increase immediately (within 1 h) after intake of a high-glucose diet, and that the administration of human insulin decreases elevated hemolymph sugar levels in silkworms. In this hyperglycemic silkworm model, however, administration of pioglitazone or metformin, drugs used clinically for the treatment of type II diabetes, have no effect. Therefore, here we established a silkworm model of type II diabetes for the evaluation of anti-diabetic drugs such as pioglitazone and metformin. Silkworms fed a high-glucose diet over a long time-period (18 h) exhibited a hyperlipidemic phenotype. In these hyperlipidemic silkworms, phosphorylation of JNK, a stress-responsive protein kinase, was enhanced in the fat body, an organ that functionally resembles the mammalian liver and adipose tissue. Fat bodies isolated from hyperlipidemic silkworms exhibited decreased sensitivity to human insulin. The hyperlipidemic silkworms have impaired glucose tolerance, characterized by high fasting hemolymph sugar levels and higher hemolymph sugar levels in a glucose tolerance test. Administration of pioglitazone or metformin improved the glucose tolerance of the hyperlipidemic silkworms. These findings suggest that the hyperlipidemic silkworms are useful for evaluating the hypoglycemic activities of candidate drugs against type II diabetes.


Subject(s)
Bombyx/drug effects , Diabetes Mellitus, Type 2/drug therapy , Drug Evaluation, Preclinical , Hypoglycemic Agents/pharmacology , Animals , Bombyx/metabolism , Diabetes Mellitus, Experimental , Diet , Fat Body/metabolism , Glucose Intolerance , Glucose Tolerance Test , Hyperglycemia/drug therapy , Hyperglycemia/metabolism , Insulin Resistance , JNK Mitogen-Activated Protein Kinases/metabolism , Metformin/pharmacology , Phenotype , Phosphorylation , Pioglitazone , Thiazolidinediones/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL